Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / COM
-
Number of holders
-
159
-
Total 13F shares, excl. options
-
49,339,027
-
Shares change
-
+1,538,586
-
Total reported value, excl. options
-
$824,462,207
-
Value change
-
+$27,617,409
-
Put/Call ratio
-
72%
-
Number of buys
-
94
-
Number of sells
-
-53
-
Price
-
$16.71
Significant Holders of AIMMUNE THERAPEUTICS INC - COM (AIMT) as of Q2 2020
196 filings reported holding AIMT - AIMMUNE THERAPEUTICS INC - COM as of Q2 2020.
AIMMUNE THERAPEUTICS INC - COM (AIMT) has 159 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49,339,027 shares
.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (5,274,902 shares), VANGUARD GROUP INC (4,202,544 shares), BlackRock Inc. (3,926,120 shares), STATE STREET CORP (3,725,138 shares), Palo Alto Investors LP (3,318,212 shares), EVENTIDE ASSET MANAGEMENT, LLC (3,193,117 shares), FMR LLC (2,306,208 shares), VICTORY CAPITAL MANAGEMENT INC (2,070,531 shares), FIERA CAPITAL CORP (1,575,531 shares), and RICE HALL JAMES & ASSOCIATES, LLC (1,093,144 shares).
This table shows the top 159 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.